A brief introduction to nmnh powder | BONTAC

A brief introduction to nmnh powder | BONTAC

NMNH effectively increased cellular NAD+ content and this process was mainly Dependent on NMNAT NMNH effectively increased cellular NAD+ content and this process was mainly Dependent on NMNAT NMNH is naturally present in the kidney, NMNH is rapidly converted to NAD+ in biological cells at a rate and concentration more than twice that of NMN, while elevating NAD+ levels in a variety of tissues. NMNH reduces cellular damage in the presence of hypoxia and enhances cellular repair. In addition, NMNH also significantly increases NADH levels in biological cells and inhibits cellular glycolysis and the tricarboxylic acid cycle.
Get A Quote

Advantages of NMNH

NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service

Advantages of NADH

NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service

Advantages of NAD

NAD:  1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products

Advantages of MNM

NMN:  1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University

about us

We Have The Best Solutions for Your Business

Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.

As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.

In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.

Learn More

NADH powder manufacturing method

The main methods of NMNH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme becomes the mainstream method owing to the advantages of pollution free, high level of purity and

NADH powder manufacturing method

NMNH is more potent than NMN

When applied to cultured cells, the NMNH is shown to be more efficient than NMN as it was able to “significantly increase NAD+ at a ten times lower concentration (5 µM) than that needed for NMN”. Moreover, NMNH shows to be more effective , as at 500 µM concentration, it achieved “an almost 10-fold increase in the NAD+ concentration, while NMN was only able to double NAD+ content in these cells, even at 1 mM concentration.”.
Interestingly, NMNH also appears to act quicker and has a longer-lasting effect compared to NMN. According to the authors, NMNH induces a “significant increase in NAD+ levels within 15 minutes”, and “NAD+ steadily increased for up to 6 hours and remained stable for 24 hours, while NMN reached its plateau after only 1 hour, most likely because the NMN recycling pathways to NAD+ had already become saturated.”.

NMNH is more potent than NMN

BONTAC NMNH product features and advantages

1. "Bonzyme" Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder.
2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability.
3. Exclusive “Bonpure” seven-step purification technology, high purity (up to 99%) and stability of production of NMNH powder
4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder
5. Provide one-stop product solution customization service

BONTAC NMNH product features and advantages
User Reviews

What users say about BONTAC

BONTAC is a reliable partner that we have been working with for many years. The purity of their coenzyme is very high. Their COA can achieve relatively high test results.

Front

I discovered BONTAC in 2014 because David's article in cell about NAD and NMN related showed that he used BONTAC's NMN for his experimental material. Then we found them in China. After so many years of cooperation, I think it is a very good company.

Hanks

I think green, healthy and high purity are the advantages of BONTAC's products compared with others. I still work with them to this day.

Phillip

In 2017, we chose BONTAC's coenzyme, during which our team encountered many technical problems and consulted their technical team, which were able to give us good solutions. Their products are shipped very fast and they work more efficiently.

Gobbs
Frequently Asked Question

Do you have any question?

NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.

Nicotinamide adenine dinucleotide (NAD+ ) homeostasis is constantly compromised due to degradation by NAD+ -dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors.

First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.

Our updates and blog posts

Maternal NAD Precursor Supplementation to Reduce the Risk of Developing CNDD

1. Introduction Nicotinamide adenine dinucleotide (NAD) has been unveiled to be essential for embryonic development. Patients with genetic variants in the NAD+ de novo synthesis pathway often have congenital NAD deficiency disorder (CNDD), a multisystem condition inherited in an autosomal recessive manner. In the context of NAD+ deficiency, all organs and systems, not just vertebrae, heart, kidneys, and limbs, may be affected. 2. The association between NAD synthetase 1 (NADSYN1)  and CNDD Individuals delivering biallelic NADSYN1 variants share similar clinical features to those with CNDD. Up till now, almost all of the identified CNDD cases can be attributed to biallelic loss-of-function variants in any of 3 nonredundant genes of the NAD de novo synthesis pathway, including kynureninase (KYNU), 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), or NADSYN1. Among individuals with CNDD identified to date, those with biallelic pathogenic NADSYN1 variants are the most diverse in phenotype. 3. The impact of NADSYN1 variants upon enzymatic activity and phenotype Specifically, NADSYN1 can catalyse the amidation of nicotinic acid adenine dinucleotide (NaAD) to NAD. Biallelic pathogenic variants in NADSYN1 cause a metabolic block in both the de novo pathway and the Preiss-Handler pathway, leading to NAD deficiency. Biallelic NADSYN1 loss-of-function variants impact the NAD metabolome of humans. Post-birth phenotypes involve feeding difficulties, developmental delay, short stature, etc. 4. Mouse embryogenesis disrupted by the loss of NADSYN1 In NADSYN1-/- mouse embryos, NAD-dependent malformations occur when maternal dietary NAD precursors are limited during gestation. The affected Nadsyn1-/- embryos most frequently present malformations of the kidneys, eyes, and lungs. 5. The preventative effect of amidated NAD precursor supplementation against CNDD NADSYN1-dependent embryo loss and malformation in mice are preventable by dietary supplementation of amidated NAD precursors (NMN and NAM) during pregnancy. Maternal diet–derived NAD precursors primarily determine the development of healthy embryos. 6. Conclusion NAD-boosting supplements are essential for individuals with biallelic loss-of-function variants in NADSYN1. Maternal NAD precursor supplementation, to some extent, can reduce the risk of developing CNDD. Reference Szot JO, Cuny H, Martin EM, et al. A metabolic signature for NADSYN1-dependent congenital NAD deficiency disorder. J Clin Invest. 2024;134(4):e174824. Published 2024 Feb 15. doi:10.1172/JCI174824 About BONTAC BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and its precursors (eg. NMN and NR), with various forms to be selected (eg. endoxin-free IVD-grade NAD, Na-free or Na-containing NAD; NR-CL or NR-Malate). High quality and stable supply of products can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.

Hello! 2024 CPHI

On June 19th~21st, 2024, Chemical Pharmaceutical Ingredient (CPHI) Exhibition will be held in Shanghai New International Expo Center, China. BONTAC will display premium raw materials of coenzyme and natural products at Booth No. W4G27 in 2024 CPHI, including but not limited to NAD, NMNH, NADH, Rare Ginsenoside Rh2/Rg3, Stevioside RA/RD/RM, Pro-Xylane, Ergothioneine, Varginsen® Ginseng Powder and Ori-cozyme®Yeast Ribonucleotide. Dr Cheung, the chief scientist and founder of BONTAC, is invited to participate in Seminar on Biomanufacturing and Cosmetic Ingredients, the first CPHI Conference on biomanufacturing innovation and development. About CPHI 2024 CPHI is a premier event of pharmaceutical industry worldwide, bringing together suppliers and buyers from the entire pharmaceutical supply chain. Shanghai New International Expo Center covers an area of 210,000 square meters. The exhibition is expected to attract more than 3,500 domestic and international exhibitors and over 90,000 domestic and overseas professional visitors. CPHI 2024 is a feast of knowledge and wisdom. Many industry leaders are invited to share their experiences and exchange their insights into the pharmaceutical industry. There are a series of exciting activities on the exhibition site, including social dinner, Happy Hour, factory tour, theme forum, technical seminar, product show, exploration tour, product launch, etc. BONTAC profile Bontac Bio-Engineering (Shenzhen) Co., Ltd. (also referred to as BONTAC) is a high-tech enterprise established in July 2012, with self-owned factories and 170+ invention patents. BONTAC integrates R&D, production and sales. There are six major series of product in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates. By virtue of the first whole-enzyme catalysis technology in China, BONTAC takes the industry lead in its niche field of coenzyme. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields.

Rare Ginsenosides: Potential Treatment for Hyperuricemia and Spermatozoa Damage

Introduction With changes in lifestyles and dietary structure, hyperuricemia shows an increasing prevalence year by year, which may become the second largest metabolic disease after diabetes mellitus, as well as the fourth most common chronic disease after hypertension, hyperglycemia, and hyperlipidemia. Recent research unravels that hyperuricemia is closely related to male infertility and affects semen quality. Long-term hyperuricemia, especially among younger individuals, may threaten the reproductive capacity of men at a reproductive age. Noteworthily, rare ginsenosides (RGs), the main active compounds in ginseng, have been proven to be effective in alleviating hyperuricemia and concomitant spermatozoa damage. About hyperuricemia Hyperuricemia is a metabolic disease caused by a purine metabolism disorder or insufficient excretion of uric acid. In traditional Chinese medicine (TCM), hyperuricemia is generally categorized as "gout" and "paralysis", which requires differential diagnosis and treatment. As described in the classic traditional Chinese medical text Shang Han Lun (On Cold Damage), ginseng can be used for hyperuricemia treatment. TCM Type of Hyperuricemia Treatment Endoretention of damp heat Clearing heat and dampness; promoting blood circulation to remove meridian obstruction Liver qi stagnation Soothing liver and relieving depression; regulating qi and relieving pain Spleen vacuity with damp encumbrance Invigorating spleen and removing dampness; promoting blood circulation to remove meridian obstruction Renal deficiency and blood stasis Invigorating kidney to replenish essence; promoting blood circulation to remove meridian obstruction Restoration of histopathological changes in the liver, kidney, and testes following treatment of RGs RGs counteract histopathological changes and alleviate the pathological lesions in the kidney and testes. No significant damage is observed in liver of mice with PO-induced hyperuricemia. Post RGS treatment, the renal tubular vacuolar degeneration, dilatation and swelling in potassium oxonate (PO)-induced hyperuricemia are mitigated. In addition to a slight increase in the thickness of the peritubular membrane, PO group shows a significant reduced trend towards the internal diameter of the seminiferous tubules as well as the number of germ cell layers in the tubular wall and mature spermatozoa. Yet, these trends are reversed. Meanwhile, the number of germ cell layers and sperm density are restored in the RGs group. Preventive and ameliorative effects of RGs in mice with PO-induced hyperuricemia RGS containing Rg3, Rk1, Rg6, and Rg5 could repress serum uric acid (UA) level, serum and hepatic xanthine oxidase (XO) activity, renal renal creatinine (CRE) and renal creatinine (CRE) levels, the accumulation of malondialdehyde (MDA) in the kidneys and the production of renal IL-1β, while promoting renal superoxide dismutase (SOD) and glutathione (GSH) activities in mice with PO-induced hyperuricemia. Moreover, RGs can improve sphingolipid metabolism, pyrimidine metabolism, and other metabolic pathways. RGs could increase gut microbial diversity, restore the Firmicutes/Bacteroidetes (F/B) ratio, and adjust the intestinal microbial balance. Remarkably, there is a correlation between differentially metabolites and the gut microbiota (Lactobacillus and Akkermansia). Conclusion RGs may be a candidate for the prevention and amelioration of hyperuricemia and concomitant sperm damage. On the one hand, RGs can alleviate PO-induced hyperuricemia by inhibiting XO activity, restoring renal function and regulating the intestinal flora balance. On the other hand, RGS can ameliorate the sperm damage associated with hyperuricemia by regulating sphingolipid metabolism, ameliorating renal oxidative stress, reducing inflammation, reversing renal injury, and repairing testicular tissue. Reference Ji X, Yu L, Han C, et al. Investigating the effects of rare ginsenosides on hyperuricemia and associated sperm damage via nontargeted metabolomics and gut microbiota. J Ethnopharmacol. 2024;332:118362. doi:10.1016/j.jep.2024.118362 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 180 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.

Get In Touch

Don't hesitate to contact with us

Sending your message. Please wait...